1 / 34

Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214

Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214. Enrique Grande Head of Medical Oncology Director of Clinical Research. Disclosures. Honoraria for ad boards and/or lectures:

fansler
Download Presentation

Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rol de la IO en el Tratamiento del Cáncer Renal:CheckMate 214 Enrique Grande Head of Medical Oncology Director of Clinical Research

  2. Disclosures Honoraria for ad boards and/or lectures: Pfizer, BMS, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, Celgene Research Grants: Pfizer, Astra Zeneca, MTEM/Threshold, Roche, IPSEN, Lexicon Leadership roles in medical societies: ENETS, GETNE and GETHI Stocks or ownership interest: None

  3. ESMO 2019 Guidelines 1st Line mRCC Escudier B, et al. AnnOncol 2019

  4. Current European Association of Urology updated Guidelines Powles T, et al. EurUrol 2017

  5. CheckMate 214: Changing paradigms in mRCC Motzer RJ, et al. NEnglJMed 2018

  6. Curti BD. NEnglJMed 2018

  7. Curti BD. NEnglJMed 2018

  8. CheckMate 214 Trial Design Motzer RJ, et al. NEnglJMed 2018

  9. CheckMate 214: Baseline characteristics Motzer RJ, et al. NEnglJMed 2018

  10. CheckMate 214: Overall Survival in the ITT (follow up 30m) TannirN, et al. ASCO GU 2019

  11. CheckMate 214: Overall Survival by IMDC Risk TannirN, et al. ASCO GU 2019

  12. CheckMate 214: Investigator-Assessed PFS ITT Patients TannirN, et al. ASCO GU 2019

  13. CheckMate 214: Investigator-Assessed PFS by IMDC risk TannirN, et al. ASCO GU 2019

  14. CheckMate 214: Time from randomization to subsequent systemic anticancer therapy initiation or death in the ITT population McDermott DF, et al. ASCO GU 2019

  15. CheckMate 214: Time from randomization to subsequent systemic anticancer therapy initiation or death in IMDC favorable risk pts McDermott DF, et al. ASCO GU 2019

  16. Treatment Free Survivalhealthstates and endpoints McDermott DF, et al. ASCO GU 2019

  17. Treatment Free Survival in ITT patients who discontinued protocol therapy McDermott DF, et al. ASCO GU 2019

  18. Treatment Free Survival in IMDC favorable-risk patients who discontinued protocol therapy McDermott DF, et al. ASCO GU 2019

  19. TFS in IMDC Intermediate/Poor-Risk Patients Who Discontinued Protocol Therapy and Had CR/PR or SD McDermott DF, et al. Oralpresentationat the 7th International KidneyCancerSimposium. Miami 2018

  20. CheckMate 214: Investigator-Assessed Response by RECIST v1.1 TannirN, et al. ASCO GU 2019

  21. CheckMate 214: Objective response rate by Age Motzer RJ, et al. NEnglJMed 2018

  22. CheckMate 214: Duration of Response Rini BI, et al. Presented at the 17th International Kidney Cancer Symposium; November 2–3, 2018; Miami, FL, USA

  23. CheckMate 214: Overall Survival Rini BI, et al. Presented at the 17th International Kidney Cancer Symposium; November 2–3, 2018; Miami, FL, USA

  24. CheckMate 214 Trial: Treatment-related AEs ITT Motzer RJ, et al. NEnglJMed 2018

  25. CheckMate 214 Trial: Time to onset of any-grade treatment-related select AEs in the NIVO+IPI arm Tannir N, et al. Presented at the 13th European International Kidney Cancer Symposium; April 27–28, 2018; Prague, Czech Republic

  26. Treatment-Related AEs Over Time by Most Common System Organ Class (All Treated Patients) TannirN, et al. ASCO GU 2019

  27. Treatment-related Aes leading to discontinuation within 100 days of last dose in the NIVO+IPI arm TannirN, et al. ASCO GU 2019

  28. Total NIVO doses received in pts who discontinued due to treatment-related AEs in the NIVO+IPI arm TannirN, et al. ASCO GU 2019

  29. Best Overall Response per Investigator by AEs TannirN, et al. ASCO GU 2019

  30. Overall Survival by treatment-related AEs discontinuation TannirN, et al. ASCO GU 2019

  31. Cella D, et al. Lancet Oncol 2019

  32. CheckMate 214: Patient-reported Outcomes (FKSI-19) Cella D, et al. Lancet Oncol 2019

  33. CheckMate 214: Cost-effectiveness Analysis Wam XM, et al. JAMA Oncol 2019

  34. egrande@mdanderson.es @drenriquegrande

More Related